| Previous Close | 0.0626 |
| Open | 0.0605 |
| Bid | 0.0626 x N/A |
| Ask | 0.0655 x N/A |
| Day's Range | 0.0605 - 0.0636 |
| 52 Week Range | 0.0536 - 0.9010 |
| Volume | 8,291 |
| Avg. Volume | 13,002 |
| Market Cap | 2.812M |
| Beta (5Y Monthly) | 2.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
The company achieved strong revenue growth during the year, only to have this positive momentum halted during the last several months by a few small, however significant impacts of supply and demand. Unfortunately, this increased competition had an adverse effect on the bulk ingredient pricing model, resulting in record low margins across the industry and ultimately forcing a pivot in our sales strategies and operations to focus on branded finished products.
VANCOUVER, BC / ACCESSWIRE / December 3, 2019 / Isodiol International Inc. (CSE:ISOL)(OTCQB:ISOLF)(FSE:LB6B.F) (the "Company" or "Isodiol"), announces that it has filed its consolidated financial statements and MD&A for the three months ended September 30, 2019 and issues shares to settle debt. The Company has reported revenues of $1.878M for its second quarter. The Company attributes the decrease in revenue primarily to management restructuring and the continued focus on long term, higher margin growth.
VANCOUVER, BC / ACCESSWIRE / October 9, 2019 / Isodiol International Inc. (CSE:ISOL) (OTCQB:ISOLF) (FSE:LB6B.F) (the "Company" or "Isodiol"), announces it has entered into a strategic relationship with Vitamin Shoppe, Inc. (VSI) ("The Vitamin Shoppe") for the launch of the Company's Iso-Sport products. Iso-Sport will serve as a leading brand of sports performance cannabinoid (CBD) hemp extract products at The Vitamin Shoppe. The Vitamin Shoppe is an omni-channel specialty retailer of nutritional products that continues to expand its CBD hemp extract offerings to meet consumer demand and serve as a trusted retailer of quality health and wellness supplements.
VANCOUVER, BC / ACCESSWIRE / October 4, 2019 / Isodiol International Inc. (CSE:ISOL) (OTCQB:ISOLF) (FSE:LB6B.F) (the "Company" or "Isodiol"), announces that Pawceuticals, the CBD-based product line that naturally helps to restore a pet's health and overall wellness, is now available to purchase across the United States. The Pawceuticals functional CBD pet products are designed for dogs and cats and are scientifically formulated with a proprietary blend of adaptogens that may aid in comfort, calming, healthy gums support, immune support, itch support, joint support, kennel cough support, kidney support, liver support, urinary support and anti-aging. The Company's products are now available online and is also in the process of building their retail channels as well.
VANCOUVER, BC / ACCESSWIRE / October 3, 2019 / Isodiol International Inc. (CSE:ISOL)(OTCQB:ISOLF)(FSE:LB6B.F) (the "Company" or "Isodiol"), announces the appointment of Andrew Alvis to serve as the Company's President. Mr. Alvis has diverse experience in all aspects of leadership, operational efficiency and revenue growth. Andrew held the position of Senior Finance Executive at Bank of America where he managed all accounting and finance system impacts for each acquisition as well as implementing strategies across mortgage servicing platforms to accommodate home loan delinquencies driven by the financial crisis of 2008.
Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces that it has filed its consolidated financial statements and MD&A for the three months ended June 30, 2019. The Company has reduced its operational expenditures by $3M compared to the three months ended June 30, 2018 and by $13M compared to the most recently completed three months ended March 31, 2019.
Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces that it has filed its audited consolidated financial statements and MD&A for the year ended March 31, 2019.
The Company obtained a management cease trade order dated July 30, 2019 from the relevant securities regulators as contemplated by National Policy 12-203 Management Cease Trade Orders of the Canadian Securities Administrators. The delay of the Filings resulted from delays in the Company obtaining access to accounting information following dispositions of subsidiaries over which the Company no longer has management influence. The Company notes the audit is nearly complete and continues to expect to file the Filings on or before August 16, 2019. The Company will comply with the requirements of the alternative information guidelines set out in the National Policy. The Company is not subject to any insolvency proceedings.
Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), today announces a delay in the filing of its audited annual financial statements, related management’s discussion and analysis and supporting officer certificates for the financial year ended March 31, 2019 (the “Filings”). The Filings are required to be made with the relevant securities regulatory authorities on or before July 29, 2019. The anticipated delay of its Filings is a result of delays in getting access to accounting information pursuant to dispositions of subsidiaries for which the Company no longer has management influence over. The Company notes that such delays have been resolved and the Company is now in the final stages of the audit and anticipates completing its Filings before August 16, 2019.
VANCOUVER, British Columbia, July 18, 2019 -- Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces that the asset.
VANCOUVER, British Columbia, June 10, 2019 -- Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), today announces the voting.
Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces that it will hold its annual general meeting of the Company's shareholders (the "Meeting") at 10:00 a.m. (Central Time) on June 6, 2019, at the Westin Santa Fe Hotel (Ballroom A) in Mexico City, Mexico.
Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is exhibiting at The Efficient Collaborative Retail Marketing Company (“ECRM”) Efficient Program Planning Sessions (“EPPS”): Pet EPPS, through May 01, 2019. This event also marks the debut of Pawceuticals, the Company’s CBD-based product line that naturally aids in restoring a pet’s health. The EPPS within the ECRM event series allow vendors to have direct discussions with more than 80 retailers and other brands about business objectives, such as product launches, marketing campaigns, and more.
Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces the commencement of its cannabidiol (CBD) vending machine program with an initial launch of Iso-Sport™ products in 20 Powerhouse Gym (“Powerhouse”) locations across the United States. This announcement follows Isodiol’s September 14, 2018 announcement that it entered into an agreement with Powerhouse to be the preferred vendor of CBD performance products in Powerhouse gyms. Powerhouse is one of the largest health club licensing organizations in the world, with over 1.2 million gym members. Today, Powerhouse continues to experience substantial growth opportunities, allowing the Company to target a growing consumer base for CBD products.